This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Oncology Podcasts

ASCO GU 2025

Quick Data Digest Podcast Series on Prostate Cancer Advances

ASCO GU 2025

Welcome to our dedicated ASGO GU ‘quick data digest’ 2-part podcast series, where we present exclusive insights from leading oncologists on the latest data released in prostate cancer treatment, filmed at the ASGO GU Annual Congress in San Francisco 2025.

NUBEQA® (darolutamide) Prescribing Information

 

Featuring:

  • Dr. Danish Mazhar, (Consultant Medical Oncologist, Addenbrookes Hospital, Cambridge)
  • Prof. Amit Bahl (Consultant Clinical Oncologist, University Hospitals Bristol and Chair of the British Uro-Oncology Group)

Join Dr. Mazhar and Prof Bahl where they delve into the latest advancements in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) as discussed at the ASGO GU Congress 2025

In this episode, Dr. Mazhar explores key findings from pivotal studies, including STOPCAP, TALAPRO-2, ENZA-P and the ARASENS age subgroup analysis.

The experts provide an overview of these trials and their implications for clinical practice, equipping you with essential knowledge to enhance patient care.

Tune in to gain insights that will empower your treatment decisions in the evolving landscape of prostate cancer management.

NUBEQA Prescribing Information

RECOMMEND STUDY

Prospective real-world data evaluation of clinical outcomes in metastatic hormone sensitive prostate cancer (mHSPC) patients treated as part of triplet therapy with darolutamide: UK multicenter RECOMMEND study.

Download Here
Speakers
    • Danish Mazhar
      Dr Danish Mazhar

    Dr Danish Mazhar is a Consultant in Medical Oncology. With a strong focus on urological cancers, he serves as Principal Investigator for numerous clinical trials involving prostate, bladder, and testicular cancers. He is an active member of the National Cancer Research Network Testis Cancer Clinical Studies Group and has previously chaired its Quality of Life Subgroup. Additionally, he is a member of the Executive Committee of the Association of Cancer Physicians.

    • Amit Bahl
      Professor Amit Bahl

    Professor Amit Bahl is Consultant Clinical Oncologist at Bristol Cancer Institute, University Hospitals Bristol, Bristol, UK. He has also been an expert adviser to the National Institute for Health and Care Excellence (NICE) for technology appraisals on new drugs, is actively involved in research and is the Clinical Co-lead for National Kidney Cancer Audit and Chairperson of British Uro-oncology Group.

Gathering consensus on mHSPC Treatment
NUBEQA® (darolutamide)
PP-NUB-GB-2230, March 2025
P3 Prostate Cancer Forum: 2024
perspectives, possibilities, progress
PP-NUB-GB-2012, January 2025
ESMO 2024 Shorts Series
NUBEQA® (darolutamide)
PP-NUB-GB-2082, January 2025

PP-NUB-GB-2229 | March 2025